These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36451848)

  • 41. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
    Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
    Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nasal brushing molecular endotyping distinguishes patients with chronic rhinosinusitis with nasal polyps with better response to dupilumab.
    Gayvert K; Desrosiers M; Laidlaw TM; Mannent LP; Patel K; Horowitz J; Amin N; Jagerschmidt A; Hamilton JD; Lim WK; Harel S
    J Allergy Clin Immunol; 2024 Sep; 154(3):619-630. PubMed ID: 38880251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
    Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care.
    Galletti C; Barbieri MA; Ciodaro F; Freni F; Galletti F; Spina E; Galletti B
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
    Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
    Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
    Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
    Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients.
    De Corso E; Porru DP; Corbò M; Montuori C; De Maio G; Mastrapasqua RF; Panfili M; Spanu C; Di Bella GA; D'Agostino G; Rizzuti A; Passali GC; Galli J
    Clin Otolaryngol; 2024 Jul; 49(4):481-489. PubMed ID: 38711363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
    Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
    Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dupilumab improves sleep quality in chronic rhinosinusitis with nasal polyps.
    Riva G; Garetto M; Borgione M; Piazza F; Prizio C; Dellea D; Albera A; Canale A; Pecorari G
    Am J Otolaryngol; 2024; 45(4):104310. PubMed ID: 38677148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
    Kariyawasam HH
    Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
    [No Abstract]   [Full Text] [Related]  

  • 52. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
    Dharmarajan H; Falade O; Lee SE; Wang EW
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
    Caminati M; Maule M; Benoni R; Bagnasco D; Beghè B; Braido F; Brussino L; Cameli P; Candeliere MG; Carpagnano GE; Costanzo G; Crimi C; D'Amato M; Del Giacco S; Guarnieri G; Yacoub MR; Micheletto C; Nicola S; Olivieri B; Pini L; Schiappoli M; Vaia R; Vianello A; Visca D; Spanevello A; Senna G
    Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38397992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
    Geng B; Bachert C; Busse WW; Gevaert P; Lee SE; Niederman MS; Chen Z; Lu X; Khokhar FA; Kapoor U; Pandit-Abid N; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):732-741. PubMed ID: 34954123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps.
    Gangl K; Liu DT; Bartosik T; Campion NJ; Vyskocil E; Mueller CA; Knerer B; Eckl-Dorna J; Schneider S
    J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating T Cell Subsets and ILC2s are Altered in Patients With Chronic Rhinosinusitis With Nasal Polyps After Dupilumab Treatment.
    Matsuyama T; Takahashi H; Tada H; Chikamatsu K
    Am J Rhinol Allergy; 2023 Jan; 37(1):58-64. PubMed ID: 36214075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
    Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
    Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
    Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
    Hopkins C; Mullol J; Khan AH; Lee SE; Wagenmann M; Hellings P; Fokkens W; Msihid J; Nair R; Kamat S; Nash S; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    Otolaryngol Head Neck Surg; 2024 Apr; 170(4):1173-1182. PubMed ID: 38156522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The "real life" efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP.
    Campion NJ; Brugger J; Tu A; Stanek V; Brkic FF; Bartosik TJ; Liu DT; Hoehl BS; Gangl K; Eckl-Dorna J; Schneider S
    J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):56. PubMed ID: 37674253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.